-

USAntibiotics Names Mark Tengler Senior Vice President of Manufacturing Technologies

BRISTOL, Tenn.--(BUSINESS WIRE)--USAntibiotics, the only U.S. manufacturer of penicillin-based Amoxicillin and Amoxil Clavulanate, the life-saving antibiotics commonly known as Amoxil® and Augmentin®, today announced the appointment of Mark Tengler to the position of senior vice president of manufacturing technologies. A seasoned pharmaceutical leader with more than three decades of expertise, Tengler will oversee all aspects of manufacturing at the company’s world-class 394,000-square-foot facility, including antibiotics processing and packaging, plastics processing, engineering, maintenance, building services and warehouse management.

"We are delighted to welcome Mark to the USAntibiotics leadership team," said Patrick Cashman, president, USAntibiotics. "His extensive experience in pharmaceutical manufacturing, regulatory compliance and process innovation align seamlessly with our deep commitment to operational excellence. As we continue to expand operations and strengthen the nation’s domestic supply of life-saving antibiotics, his leadership will be instrumental in advancing our mission and positively impacting millions of Americans."

Tengler brings to his role a proven track record of driving innovation, optimizing complex workflows and leading cross-functional teams to achieve strategic business objectives. His expertise in developing integrated approaches that align facility operations has fueled sustained growth and success across highly competitive markets.

Before joining USAntibiotics, Tengler held executive leadership roles at organizations that include Spectrix Therapeutics, LLC and PharmaFab, LLC. In 2006, he transitioned PharmaFab into Neos Therapeutics, Inc., where he served as founder, president and chief technology officer, and was instrumental in the company’s successful Nasdaq debut.

About USAntibiotics

USAntibiotics is the only U.S. manufacturer of Amoxicillin and Amoxicillin Clavulanate, commonly known as Amoxil® and Augmentin®. Based in Bristol, Tennessee, it operates a world-class, 394,000-square-foot antibiotics production facility with the sole focus of making quality, life-saving antibiotics widely available for the benefit of all Americans. USAntibiotics is part of the Jackson Healthcare® family of companies. For more information, visit www.us-antibiotics.com.

Contacts

media@us-antibiotics.com

Industry:

USAntibiotics

Release Versions
English

Contacts

media@us-antibiotics.com

More News From USAntibiotics

USAntibiotics Awarded FDA National Priority Voucher for Domestic Manufacturing of Critical Antibiotic

BRISTOL, Tenn.--(BUSINESS WIRE)--USAntibiotics, the country’s only domestic manufacturer of amoxicillin (Amoxil®) and amoxicillin clavulanate (Augmentin®), announced today that the U.S. Food and Drug Administration (FDA) selected its Augmentin XR product for the agency's inaugural Commissioner's National Priority Voucher (CNPV) Program. The new voucher promises a review decision within one to two months following submission of a complete application, collapsing the typical 10 to 12-month FDA ti...

USAntibiotics Working with Walmart and McKesson to Support U.S. Manufacturing of Amoxicillin

BRISTOL, Tenn.--(BUSINESS WIRE)--USAntibiotics, the nation’s lone remaining manufacturer of amoxicillin and amoxicillin clavulanate, today announced a new collaboration with Walmart and McKesson through their joint venture partner ClarusONE Sourcing Services to provide domestically manufactured antibiotics made by USAntibiotics in the United States for millions of patients nationwide. The collaboration will see USAntibiotics supply millions of life-saving doses of amoxicillin directly to Walmar...

USAntibiotics Appoints Eric Wesoloski Vice President of Quality and Regulatory Affairs

BRISTOL, Tenn.--(BUSINESS WIRE)--USAntibiotics, the sole licensed American manufacturer of penicillin-based Amoxicillin and Amoxil Clavulanate, the life-saving antibiotics commonly known as Amoxil® and Augmentin®, today announced the appointment of Eric Wesoloski to the position of vice president of quality and regulatory affairs. In this role, Wesoloski leads all aspects of quality assurance and control, compliance, regulatory affairs and pharmacovigilance related to the manufacturing, packagi...
Back to Newsroom